"spectral CT parameters may be useful for predicting
Ki-67 expression and the presence of EGFR mutation in NSCLC."
Sci Rep. 2020 Feb 26;10(1):3436.
In our study, we found that LCRC and RCC showed different features on the clinicopathological and molecular markers in eastern China CRC patients.
Front. Genet., 25 February 2020
Overlapping morphologic features and comparable mutation profiles support that peripheral GPs/MPs and CMPTs/BAs are on the same disease spectrum. We propose expanding the concept of CMPT/BA and including GP and MP in the CMPT/BA family.
Histopathology. 2020 Feb 25.
"Intratumoral genetic heterogeneity of LACs was demonstrated associated with histological patterns.
Heterogeneous PD-L1 expression in higher level usually occurred in solid component both in EGFR mutated and EGFR
wild-typed LACs. EGFR mutated LACs heterogeneously had sensitizing and resistant mutation and was accompanied
with PD-L1 expression, but discordant among histological constituents. Immune checkpoint inhibitor combined with
third generation EGFR tyrosine kinase inhibitor should be more effective to these LACs."
BMC Cancer. 2020 Feb 24;20(1):148.
The proportion of nonsquamous NSCLC patients with confirmed biomarker status for first-line treatment was considered insufficient and in need of improvement.
Ther Adv Med Oncol. 2020 Feb 22;12:1758835920904522.
False negative of ALK IHC, FISH and NGS results were found in our cohort, but none was false ALK positive. False ALK negatives should be more concerned than false positives. ALK rearrangements with cryptic ALK fusion patterns could be identified using our algorithm. Non-squamous non-small cell lung cancer was recommended for priority detection.
J Cancer Res Clin Oncol. 2020 Mar 3.